Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890326310> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W2890326310 endingPage "TPS8051" @default.
- W2890326310 startingPage "TPS8051" @default.
- W2890326310 abstract "TPS8051 Background: Multiple myeloma (MM) remains an incurable hematologic malignancy despite the advent of new classes of drugs, including immunomodulatory agents, proteasome inhibitors, and monoclonal antibodies. The success and synergistic activity of immunotherapy (IMT) in solid tumors and hematologic malignancies has fueled their investigation in MM. HDT/ASCT as consolidation or as treatment for relapse remains a cornerstone for improving overall survival. HDT/ASCT transiently eliminates immune-suppressive cell populations and provides a viable IMT platform. Reinfusion of PBLs harvested pre-HDT induces immune responses, supporting its inclusion in IMT combinations. This study evaluates the effect of IMT, using tremelimumab (T), an anti-CTLA-4 monoclonal antibody, and durvalumab (D), an anti-PD-L1 monoclonal antibody, together with autologous PBL reinfusion and starting T ± D at Day 100 and earlier (Day 30) post-ASCT. Methods: This ongoing Phase 1, open-label, multicenter study (NCT02716805) evaluates the safety and preliminary efficacy of T and D administered on 2 schedules in MM patients at high risk for relapse as outlined below. Cohort initiation requires dose-limiting toxicity in < 2/6 patients in the previous cohort. The primary endpoint is safety. Secondary endpoints are objective response rate per IMWG, minimal residual disease, progression free and overall survival, and 100-day ASCT-related mortality. Exploratory endpoints include immunological effects and immune response. Enrollment opened 18 Nov 2016. As of 31 Dec 2016, 1 patient is enrolled in Cohort 1; enrollment is ongoing. Clinical trial information: NCT02716805. [Table: see text]" @default.
- W2890326310 created "2018-09-27" @default.
- W2890326310 creator A5006038485 @default.
- W2890326310 creator A5007088159 @default.
- W2890326310 creator A5013747091 @default.
- W2890326310 creator A5032616904 @default.
- W2890326310 creator A5032617342 @default.
- W2890326310 creator A5053639102 @default.
- W2890326310 creator A5056014801 @default.
- W2890326310 creator A5057983232 @default.
- W2890326310 creator A5067101146 @default.
- W2890326310 date "2017-05-20" @default.
- W2890326310 modified "2023-09-23" @default.
- W2890326310 title "Phase 1 study to evaluate the safety and efficacy of immunotherapy with tremelimumab and durvalumab in multiple myeloma patients receiving high dose chemotherapy and autologous stem cell transplant (HDT/ASCT) + peripheral blood lymphocyte (PBL) reinfusion." @default.
- W2890326310 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.tps8051" @default.
- W2890326310 hasPublicationYear "2017" @default.
- W2890326310 type Work @default.
- W2890326310 sameAs 2890326310 @default.
- W2890326310 citedByCount "3" @default.
- W2890326310 countsByYear W28903263102020 @default.
- W2890326310 countsByYear W28903263102022 @default.
- W2890326310 countsByYear W28903263102023 @default.
- W2890326310 crossrefType "journal-article" @default.
- W2890326310 hasAuthorship W2890326310A5006038485 @default.
- W2890326310 hasAuthorship W2890326310A5007088159 @default.
- W2890326310 hasAuthorship W2890326310A5013747091 @default.
- W2890326310 hasAuthorship W2890326310A5032616904 @default.
- W2890326310 hasAuthorship W2890326310A5032617342 @default.
- W2890326310 hasAuthorship W2890326310A5053639102 @default.
- W2890326310 hasAuthorship W2890326310A5056014801 @default.
- W2890326310 hasAuthorship W2890326310A5057983232 @default.
- W2890326310 hasAuthorship W2890326310A5067101146 @default.
- W2890326310 hasConcept C121608353 @default.
- W2890326310 hasConcept C126322002 @default.
- W2890326310 hasConcept C143998085 @default.
- W2890326310 hasConcept C203092338 @default.
- W2890326310 hasConcept C2776364478 @default.
- W2890326310 hasConcept C2777701055 @default.
- W2890326310 hasConcept C2777742743 @default.
- W2890326310 hasConcept C2778650287 @default.
- W2890326310 hasConcept C2779050716 @default.
- W2890326310 hasConcept C2780057760 @default.
- W2890326310 hasConcept C2781433595 @default.
- W2890326310 hasConcept C535046627 @default.
- W2890326310 hasConcept C71924100 @default.
- W2890326310 hasConcept C72563966 @default.
- W2890326310 hasConceptScore W2890326310C121608353 @default.
- W2890326310 hasConceptScore W2890326310C126322002 @default.
- W2890326310 hasConceptScore W2890326310C143998085 @default.
- W2890326310 hasConceptScore W2890326310C203092338 @default.
- W2890326310 hasConceptScore W2890326310C2776364478 @default.
- W2890326310 hasConceptScore W2890326310C2777701055 @default.
- W2890326310 hasConceptScore W2890326310C2777742743 @default.
- W2890326310 hasConceptScore W2890326310C2778650287 @default.
- W2890326310 hasConceptScore W2890326310C2779050716 @default.
- W2890326310 hasConceptScore W2890326310C2780057760 @default.
- W2890326310 hasConceptScore W2890326310C2781433595 @default.
- W2890326310 hasConceptScore W2890326310C535046627 @default.
- W2890326310 hasConceptScore W2890326310C71924100 @default.
- W2890326310 hasConceptScore W2890326310C72563966 @default.
- W2890326310 hasIssue "15_suppl" @default.
- W2890326310 hasLocation W28903263101 @default.
- W2890326310 hasOpenAccess W2890326310 @default.
- W2890326310 hasPrimaryLocation W28903263101 @default.
- W2890326310 hasRelatedWork W2285109017 @default.
- W2890326310 hasRelatedWork W2589891295 @default.
- W2890326310 hasRelatedWork W2592880717 @default.
- W2890326310 hasRelatedWork W2800311363 @default.
- W2890326310 hasRelatedWork W2901721165 @default.
- W2890326310 hasRelatedWork W2909918855 @default.
- W2890326310 hasRelatedWork W3014910013 @default.
- W2890326310 hasRelatedWork W3104083510 @default.
- W2890326310 hasRelatedWork W3119432592 @default.
- W2890326310 hasRelatedWork W3170189973 @default.
- W2890326310 hasVolume "35" @default.
- W2890326310 isParatext "false" @default.
- W2890326310 isRetracted "false" @default.
- W2890326310 magId "2890326310" @default.
- W2890326310 workType "article" @default.